Report Sections

See All Reports

  • HP:0100724: Hypercoagulability
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0100724: Hypercoagulability

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (11)


    Name (Synonyms) Correlation
    drug828 Complete thrombophilic profile testing by multiplex PCR Wiki 0.50
    drug1796 Liu-Wei-Di-Huang formula Wiki 0.50
    drug3634 Yu-Ping-Feng formula Wiki 0.50
    Name (Synonyms) Correlation
    drug1230 Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter Wiki 0.50
    drug1833 Low Molecular Weight Heparin Wiki 0.50
    drug2495 Placebo for "Deficiency of Qi and Yin" Wiki 0.50
    drug3626 Xiang-Sha-Liu-Jun formula Wiki 0.50
    drug2494 Placebo for "Deficiency of Qi and Yang" Wiki 0.50
    drug3406 Tranexamic acid Wiki 0.35
    drug3705 blood sampling Wiki 0.22
    drug2514 Placebo oral tablet Wiki 0.09

    Correlated MeSH Terms (6)


    Name (Synonyms) Correlation
    D019851 Thrombophilia NIH 0.89
    D020767 Intracranial Thrombosis NIH 0.50
    D020246 Venous Thrombosis NIH 0.15
    Name (Synonyms) Correlation
    D013927 Thrombosis NIH 0.09
    D045169 Severe Acute Respiratory Syndrome NIH 0.04
    D018352 Coronavirus Infections NIH 0.04

    Correlated HPO Terms (1)


    Name (Synonyms) Correlation
    HP:0002625 Deep venous thrombosis HPO 0.15

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19

    Coronavirus COVID-19 is an emerging virus also called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Eighty percent of patients are poor or asymptomatic. However, there are major respiratory complications for some patients, requiring intensive care hospitalization and possibly leading to death in 5% of cases. One of the hypotheses put forward is that much of the pathophysiology is due to endothelial dysfunction associated with disseminated intravascular coagulation. The covid-19 pathology could induce coagulation impairment as observed during sepsis. An increase in D-dimer levels during covid-19 disease is itself associated with excess mortality. While D-dimers are highly sensitive, they are not specific for clotting activity. They may be increased in many other circumstances, particularly in inflammation. On the other hand, the infection stimulates the release of extracellular vesicles. These vesicles, of multiple cellular origin, are an actor of vascular homeostasis, and participate in the state of hyperactivation of coagulation. They have a major role in the prothrombotic state and the development of coagulopathy associated with sepsis. The aim of our monocentric prospective study would be to study early and more specific markers of hypercoagulability and markers of routine endothelial dysfunction, as soon as the patient is hospitalized, in order to predict the risk of hospitalization in intensive care.

    NCT04367662
    Conditions
    1. COVID-19
    Interventions
    1. Procedure: blood sampling
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Thrombophilia
    HPO:Hypercoagulability

    Primary Outcomes

    Measure: Clinical worsening (yes/no) of the patient during hospitalization

    Time: in the 15 days from admission

    Description: Biological analysis using initial blood sampling

    Measure: D-DIMERS plasma levels in blood

    Time: 1 hour after admission

    Description: Biological analysis using initial blood sampling

    Measure: Fibrin monomers plasma levels in blood

    Time: 1 hour after admission

    Description: Biological analysis using initial blood sampling

    Measure: Antithrombin plasma levels in blood

    Time: 1 hour after admission

    Description: Biological analysis using initial blood sampling

    Measure: Prothrombin Fragment 1 plasma levels in blood

    Time: 1 hour after admission

    Description: Biological analysis using initial blood sampling

    Measure: Prothrombin Fragment 2 plasma levels in blood

    Time: 1 hour after admission

    Description: Biological analysis using initial blood sampling

    Measure: Thrombin generation test plasma levels in blood

    Time: 1 hour after admission

    Description: Biological analysis using initial blood sampling

    Measure: Microvesicles of platelet plasma levels in blood

    Time: 1 hour after admission

    Description: Biological analysis using initial blood sampling

    Measure: Cross-linked platelets plasma levels in blood

    Time: 1 hour after admission

    Description: Biological analysis using initial blood sampling

    Measure: Willebrand Factor plasma levels in blood

    Time: 1 hour after admission

    Description: Biological analysis using initial blood sampling

    Measure: Factor VIII plasma levels in blood

    Time: 1 hour after admission
    2 Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto

    The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.

    NCT04393805
    Conditions
    1. COVID-19
    2. Hypercoagulability
    Interventions
    1. Drug: Low Molecular Weight Heparin
    MeSH:Thrombophilia
    HPO:Hypercoagulability

    Primary Outcomes

    Description: Collect and evaluate in real-life the safety data of the anti-coagulant treatments used by estimating the incidence of bleeding complications during hospitalization.

    Measure: Bleeding

    Time: 28 days

    Description: Collect and evaluate in real-life the efficacy data of the anti-coagulant treatments used by estimating the incidence of deep vein thrombosis and/or pulmonary embolism during hospitalization.

    Measure: Thrombosis

    Time: 28 days

    Description: Collect and evaluate in real-life the data by estimating incidence of intra-hospital death.

    Measure: Mortality

    Time: 28 days

    Secondary Outcomes

    Description: clinical worsening with transfer to the intensive/sub-intensive ward

    Measure: Worsening

    Time: 28 days

    Description: length of stay

    Measure: LOS

    Time: 60 days
    3 Clinical Efficacy and Safety of Extracorporeal Blood Purification to Control Hyperinflammation and Hypercoagulability in COVID-19 Patients

    Several studies have suggested a potential clinical benefit of controlling hyper inflammation triggered by SARS-CoV-2/COVID-19. Blood purification, the removal of excessive proinflammatory mediators may control disease progression and support clinical recovery. For this purpose, COVID-19 patients might benefit from treatment with AN69ST hemofilter based extracorporeal blood purification.

    NCT04478539
    Conditions
    1. Covid19
    Interventions
    1. Device: Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter
    MeSH:Thrombophilia
    HPO:Hypercoagulability

    Primary Outcomes

    Description: Systemic levels of IL-6, IL-8 and TNF-α are evaluated to assess the effect of blood purification. Measurement points: at admission, "before and after a blood purification cycle" and before discharge

    Measure: Changes in cytokine levels of Interleukin (IL) 6, IL-8 and Tumor Necrosis Factor-α (pg/mL)

    Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

    Description: Systemic levels of proinflammatory mediators are measured as a marker for disease severity. Measurement points: at admission, "before and after a blood purification cycle" and before discharge.

    Measure: Changes in inflammatory markers; C-Reactive Protein (CRP) (mg/L)

    Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

    Description: Systemic levels of thrombocytes are measured as a marker for disease severity. Measurement points: at admission, "before and after a blood purification cycle" and before discharge.

    Measure: Changes in thrombocyte counts (10^3 counts/microL)

    Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

    Description: Coagulation markers will be followed to assess the effect of systemic heparinisation, Measurement points, at admission, "before and after a blood purification cycle" and before discharge

    Measure: Changes in the coagulation marker Fibrinogen (g/L)

    Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

    Description: Duration of intensive care will be determined in relation to the number of blood purification cycles Patients will be followed for the duration of ICU stay.

    Measure: ICU length of stay after admission (days)

    Time: An expected average of 4 - 14 hospitalisation days or until hospital discharge (whichever comes first)

    Secondary Outcomes

    Description: Systemic levels of proinflammatory mediators are measured as a marker for disease severity. Measurement points: at admission, "before and after a blood purification cycle" and before discharge.

    Measure: Changes in Neutrophil-to-Lymphocyte Ratio

    Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

    Description: Coagulation markers will be followed to assess the effect of systemic heparinisation, Measurement points, at admission, "before and after a blood purification cycle" and before discharge

    Measure: Changes in the coagulation marker D-Dimers (ng/mL)

    Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

    Description: Coagulation markers will be followed to assess the effect of systemic heparinisation, Measurement points, at admission, "before and after a blood purification cycle" and before discharge

    Measure: Changes in the Activation Clotting Time (seconds).

    Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)
    4 Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events

    An estimated 22% of the global population is at an increased risk of a severe form of COVID-19, while one in four coronavirus patients admitted to intensive care unit will develop a pulmonary embolism. A major public health question remains to be investigated: why COVID-19 is mild for some, critically severe for others and why only a percentage of COVID-19 patients develop thrombosis, despite the disease's proven hypercoagulable state? Patients' intrinsic characteristics might be responsible for the deep variety of disease forms. Our study aims to assess the validity of the hypothesis according to which underlining genetic variations might be responsible for different degrees of severity and thrombotic events risks in the novel coronavirus disease. Moreover, we suspect that prothrombotic genotypes occuring in the genes that encode angiotensin-converting enzyme (ACE-DEL/INS) and angiotensinogen (AGT M235T) are involved in the unpredictable evolution of COVID-19, both in terms of severity and thrombotic events, due to the strong interactions of SARS-CoV-2 with the renin-angiotensin-aldosterone system (RAAS). Therefore, we also aim to assess the validity of the theory according to which there is a pre-existing atypical modulation of RAAS in COVID-19 patients that develop severe forms and/or thrombosis. Our hypothesis is based on various observations. Firstly, there is a substantial similarity with a reasonably related condition such as sepsis, for which there is a validated theory stating that thrombophilic mutations affect patients' clinical response. Secondly, racial and ethnic genetic differences are responsible for significant dissimilar thrombotic risks among various nations. Thirdly, an increase in stroke incidence has been reported in young patients with COVID-19, without essential thrombosis risk factors, favoring the idea that a genetic predisposition could contribute to increase the thrombotic and thromboembolic risk. Fourthly, the plasminogen activator inhibitor (PAI)-1 4G/5G inherited mutation was found to be responsible for a thrombotic state causing post-SARS osteonecrosis.

    NCT04519398
    Conditions
    1. Covid19
    2. Corona Virus Infection
    3. Thrombosis
    4. ARDS
    5. Thrombophilia
    6. Thromboses, Intracranial
    7. Thromboses, Deep Vein
    8. RAAS
    Interventions
    1. Genetic: Complete thrombophilic profile testing by multiplex PCR
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Intracranial Thrombosis Thrombosis Venous Thrombosis Thrombophilia
    HPO:Deep venous thrombosis Hypercoagulability Venous thrombosis

    Primary Outcomes

    Description: The difference of prothrombotic genotypes frequency between the three groups

    Measure: Number of patients with thrombophilic profile alterations

    Time: One year

    Secondary Outcomes

    Description: The differences of RAAS components levels between the three groups

    Measure: Number of patients with RAAS components alterations

    Time: One year

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook